- Home
- TXMD vs AEON Comparison
TXMD vs AEON Comparison
Compare TXMD & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- AEON
- Stock Information
- Founded
- TXMD 2008
- AEON N/A
- Country
- TXMD United States
- AEON United States
- Employees
- TXMD N/A
- AEON N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- AEON Health Care
- Exchange
- TXMD Nasdaq
- AEON Nasdaq
- Market Cap
- TXMD 12.3M
- AEON 13.5M
- IPO Year
- TXMD N/A
- AEON N/A
- Fundamental
- Price
- TXMD $1.23
- AEON $0.93
- Analyst Decision
- TXMD
- AEON Strong Buy
- Analyst Count
- TXMD 0
- AEON 1
- Target Price
- TXMD N/A
- AEON $7.20
- AVG Volume (30 Days)
- TXMD 506.6K
- AEON 403.3K
- Earning Date
- TXMD 11-12-2025
- AEON 11-12-2025
- Dividend Yield
- TXMD N/A
- AEON N/A
- EPS Growth
- TXMD N/A
- AEON N/A
- EPS
- TXMD N/A
- AEON N/A
- Revenue
- TXMD $2,559,000.00
- AEON N/A
- Revenue This Year
- TXMD $427.09
- AEON N/A
- Revenue Next Year
- TXMD N/A
- AEON N/A
- P/E Ratio
- TXMD N/A
- AEON N/A
- Revenue Growth
- TXMD 156.93
- AEON N/A
- 52 Week Low
- TXMD $0.70
- AEON $0.38
- 52 Week High
- TXMD $2.44
- AEON $73.44
- Technical
- Relative Strength Index (RSI)
- TXMD 59.44
- AEON 48.45
- Support Level
- TXMD $1.20
- AEON $0.88
- Resistance Level
- TXMD $1.37
- AEON $1.41
- Average True Range (ATR)
- TXMD 0.12
- AEON 0.17
- MACD
- TXMD 0.02
- AEON -0.03
- Stochastic Oscillator
- TXMD 29.85
- AEON 9.76
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.